Off-the-shelf vaccine shows promise in preventing cancers returning, study finds | Cancer research

A standard vaccine turned out to be promising in prevention of the return of pancreatic and colorectal cancer, revealed researchers.

Cancer vaccines have been the subject of promising research in recent years. The NHS in England has tested various JABs in patients thanks to the launching ramp of the cancer vaccine (CVLP).

These vaccines lead to the body’s immune system to recognize cancer cells, so that returns after treatments such as surgery can be hunted and killed, reducing the risk of returning from the disease.

Many cancer vaccines, including some of those based on mRNA technology, are personalized for patient tumors.

However, a study suggested that an unused experimental vaccine that is already carried out on a large scale could help prevent the return of pancreatic and colorectal cancer.

If they are confirmed by other trials, according to experts, the approach could be beneficial because the vaccine is likely to be cheaper and faster to access than mRNA jab, as well as less toxic than certain other therapies.

“After a long-term follow-up of this study, we were able to demonstrate that the group of patients who set up an immune response have a greater probability of not having their return from cancer and living longer compared to the historical expectation of what this patient would do,” said Professor Zev Wainberg, an oncologist at the University of California, Los Angeles, and a co-author of the study.

The authors noted that 90% of people with pancreatic cancer and 50% of people with colorectal cancer had mutations in the KRAS gene. These mutations lead to the production of modified kras protein which make cells divide and proliferate.

The writing in the journal Nature Medicine, Wainberg and his colleagues reported how they gave a vaccine called ELI-002 2P to 20 patients who had undergone surgery for pancreatic cancer and five who had been operated for colorectal cancer.

The vaccine contains peptides – long chains of amino acids, which are the constituent elements of proteins. The vaccine works by driving the T cells of the body’s immune system to recognize and kill cancer cells with mutations that cause them by producing modified KRAS proteins.

During a median follow -up of almost 20 months, the team found that the patients fell into two groups: 17 who had a strong immune response to the JAB and eight who had a lower response.

The team noted that the old group experienced a longer period before the return of its cancer and survived a longer as a whole. Overall, four of these 17 patients died during the follow -up, against seven of the eight who had a lower immune response.

However, the study is research at an early stage designed mainly to assess security, involving only 25 participants, had no control and examined two very different types of cancer.

Despite this, the experts said the results were worth noted. Siow Ming Lee, professor of medical oncology at the University College of London, which was not involved in work, suggested that the ELI-002 2P vaccine could be combined with other types of immunotherapy and could help a wider range of patients.

“With promising early results and potentially fewer side effects than current oral inhibitors, this cancer vaccine out of space could extend treatment options for cancers and justify additional tests in larger trials, in particular the exploration of its potential use in lung cancers driven by mutations in the KRAS gene,” he said.

Dr. Shivan Sivakumar from the University of Birmingham, which works on ARNA pancreatic cancer vaccines, said it was fascinating that many study patients showed a clear immune response to the standard vaccine.

But Sivakumar noted that a key advantage of personalized mRNA vaccines was that they did not have to rely on mutations in the Kras gene.

He said it was now important to carry out randomized control tests of the ELI-002 2P vaccine and follow patients over a longer period.

“How many times have we been on this path in the garden where we are really enthusiastic about science? But in fact, in the end, the real scientific experience is in patients,” added Sivakumar.